



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Obrindatamab

Cat. No.:	HY-P99762
CAS No.:	2069959-72-2
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer ^[1] .								
In Vitro	<p>MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with K_D values of 13.9, 14.7, 24.6, and 30.2 nM for human CD3ϵ/δ, cynomolgus CD3ϵ/δ, human B7-H3-His, and cynomolgus B7-H3-His, respectively^[1].</p> <p>Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines^[1].</p> <p>Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) inhibits growth and tumor regression of B7-H3-expressing tumor xenografts in human T cell or PBMC-reconstituted mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border: none;">Animal Model:</td> <td style="border: none;">NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m^{-/-} mice, Established tumor model in human T-cell reconstituted MHC1^{-/-} mice^[1]</td> </tr> <tr> <td style="border: none;">Dosage:</td> <td style="border: none;">0.004-1 mg/kg</td> </tr> <tr> <td style="border: none;">Administration:</td> <td style="border: none;">intravenous injection</td> </tr> <tr> <td style="border: none;">Result:</td> <td style="border: none;">Had antitumor activity in multiple in vivo models.</td> </tr> </table>	Animal Model:	NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m ^{-/-} mice, Established tumor model in human T-cell reconstituted MHC1 ^{-/-} mice ^[1]	Dosage:	0.004-1 mg/kg	Administration:	intravenous injection	Result:	Had antitumor activity in multiple in vivo models.
Animal Model:	NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m ^{-/-} mice, Established tumor model in human T-cell reconstituted MHC1 ^{-/-} mice ^[1]								
Dosage:	0.004-1 mg/kg								
Administration:	intravenous injection								
Result:	Had antitumor activity in multiple in vivo models.								

REFERENCES

[1]. Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA